Cardiomyopathy clinical trials at University of California Health
31 in progress, 19 open to eligible people
RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
open to eligible people ages 18 years and up
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
at UCSD
EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
open to eligible people ages 18 years and up
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or…
at UCSF
Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
open to eligible people ages 12-17
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
at UCLA
Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
open to eligible people ages 12-17
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
at UCLA
Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
at UCSD
Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
open to eligible people ages 18 years and up
The purpose of this research study is to examine the effect of cardiac sympathetic denervation (CSD) surgery on life threatening abnormal heart rhythms called ventricular tachycardia or ventricular fibrillation that can lead to sudden cardiac death. …
at UCLA
AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study
open to eligible people ages 18 years and up
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
at UCSD UCSF
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
open to eligible people ages 18-80
The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on the improvement of HCM-related symptoms and cardiac function. About…
at UCSF
Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
open to eligible females ages 18 years and up
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given…
at UC Irvine UCSD
Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
open to eligible people ages 18-75
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3…
at UCSD UCSF
Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC
open to eligible people ages 18-65
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
at UCSF
Aficamten Compared to Placebo in Adults With Symptomatic nHCM
open to eligible people ages 18-85
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
at UCLA UCSD UCSF
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
open to eligible people ages 18 years and up
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age…
at UCSD
ALXN2220 Versus Placebo in Adults With ATTR-CM
open to eligible people ages 18-90
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause…
at UCSF
Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
open to eligible people ages 18 years and up
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are…
at UCSD UCSF
Danon Disease Natural History Study
open to eligible people ages 8 years and up
The goal of this international observational study is to learn about the natural history of Danon disease in male patients >8 years of age and female patients <30 years of age. The key objectives include assessing change over time in cardiac…
at UCSD
Evaluating Pulse Oximetry Bias in Children With Darker Skin Pigmentation
open to eligible people ages up to 21 years
In this prospective study, the investigators will enroll 154 children with arterial lines to determine the accuracy of pulse oximeters in children with darker skin pigmentation. Studies in adults suggest pulse oximeters may overestimate the true…
at UCSF
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
open to eligible people ages 0-18
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This…
at UC Davis
Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
open to eligible people ages 14-65
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC.…
at UCSF
Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Sorry, in progress, not accepting new patients
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US,…
at UCSF
ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia
Sorry, currently not accepting new patients, but might later
Friedreich Ataxia is a rare condition that causes damage to the nervous system and muscles. People with Friedreich Ataxia have difficulty walking, lose sensation in their arms and legs, and have slurred speech. It can also affect the heart and many…
at UCLA
Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
at UCSF
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Sorry, in progress, not accepting new patients
To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com.
at UCSD UCSF
DCM Precision Medicine Study
Sorry, in progress, not accepting new patients
The aims of the DCM Precision Medicine Study are to test the hypothesis that DCM has substantial genetic basis and to evaluate the effectiveness of a family communication intervention in improving the uptake and impact of family member clinical…
at UCLA
Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction
Sorry, in progress, not accepting new patients
This is a non-randomized, prospective, multi-center Early Feasibility Study to evaluate the AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
at UCSF
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Sorry, in progress, not accepting new patients
This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration …
at UCLA
Long-term Safety and Tolerability of Aficamten in Adults With HCM
Sorry, accepting new patients by invitation only
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
at UCSD UCSF
AG10 in Patients with Cardiomyopathy
Sorry, in progress, not accepting new patients
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.
at UCSF
Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy
Sorry, in progress, not accepting new patients
Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late…
at UCLA
AT-001 in Patients With Diabetic Cardiomyopathy
Sorry, in progress, not accepting new patients
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.
at UC Irvine UCLA UCSD
IVTCC 2.0: a Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry
Sorry, accepting new patients by invitation only
This is a prospective multi-center international registry. The objective of this registry is to collect prospective data on patients undergoing catheter ablation for Ventricular Tachycardia (VT) and Premature Ventricular Contractions (PVC). The…
at UC Davis UCLA UCSF
Our lead scientists for Cardiomyopathy research studies include Theodore Abraham Afshan Hameed, MD Kalyanam Shivkumar, MD, PhD Barry Greenberg, MD Juan C. Alejos, MD Vasanth Vedantham Hilary Shapiro, MD Jason Bradfield, MD Nancy J. Halnon, MD Susan L. Perlman, MD Marmar Vaseghi, MD, PhD.
Last updated: